FUDR Drug Patent Profile
✉ Email this page to a colleague
When do Fudr patents expire, and what generic alternatives are available?
Fudr is a drug marketed by Hospira and is included in one NDA.
The generic ingredient in FUDR is floxuridine. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the floxuridine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fudr
A generic version of FUDR was approved as floxuridine by HIKMA on April 16th, 2000.
Summary for FUDR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 115 |
Patent Applications: | 2,552 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FUDR at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for FUDR
US Patents and Regulatory Information for FUDR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospira | FUDR | floxuridine | INJECTABLE;INJECTION | 016929-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |